Rick Doblin - MDMA-Assisted Therapy: MAPS Updates and Future Directions

MDMA-assisted therapy for PTSD is presented as a therapeutic intervention moving toward regulatory approval and global implementation. Rick Doblin highlights the importance of cultural change and legal access to psychedelics, emphasizing the need for a non-profit driven model that maintains the drug-therapy synthesis. Updates include a successful formal dispute resolution with the FDA regarding a cannabis project and ongoing international training efforts. Strategic priorities include addressing the global trauma burden via research in high-trauma, low-resource settings. Addressing the challenge of functional unblinding in psychedelic clinical trials, the approach shifts toward balancing therapeutic potential with robust, blindable research methodology. The broader aim remains long-term trauma mitigation through both specific therapies and systemic cultural shifts in drug policy.